Cargando…

Production of Modified Vaccinia Ankara Virus by Intensified Cell Cultures: A Comparison of Platform Technologies for Viral Vector Production

Modified Vaccinia Ankara (MVA) virus is a promising vector for vaccination against various challenging pathogens or the treatment of some types of cancers, requiring a high amount of virions per dose for vaccination and gene therapy. Upstream process intensification combining perfusion technologies,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gränicher, Gwendal, Tapia, Felipe, Behrendt, Ilona, Jordan, Ingo, Genzel, Yvonne, Reichl, Udo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7435511/ https://www.ncbi.nlm.nih.gov/pubmed/32762152 http://dx.doi.org/10.1002/biot.202000024

Ejemplares similares

Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systems
por: Tapia, Felipe, et al.
Publicado: (2017)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
por: Jordan, Ingo, et al.
Publicado: (2013)

Performance of an acoustic settler versus a hollow fiber–based ATF technology for influenza virus production in perfusion
por: Gränicher, Gwendal, et al.
Publicado: (2020)

Application of an Inclined Settler for Cell Culture-Based Influenza A Virus Production in Perfusion Mode
por: Coronel, Juliana, et al.
Publicado: (2020)

Continuous Influenza Virus Production in Cell Culture Shows a Periodic Accumulation of Defective Interfering Particles
por: Frensing, Timo, et al.
Publicado: (2013)

Continuous influenza virus production in a tubular bioreactor system provides stable titers and avoids the “von Magnus effect”
por: Tapia, Felipe, et al.
Publicado: (2019)

Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production
por: Tapia, Felipe, et al.
Publicado: (2016)

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases
por: Altenburg, Arwen F., et al.
Publicado: (2014)

High-cell-density cultivations to increase MVA virus production
por: Vázquez-Ramírez, Daniel, et al.
Publicado: (2018)

High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system
por: Vázquez-Ramírez, Daniel, et al.
Publicado: (2019)

Production of Defective Interfering Particles of Influenza A Virus in Parallel Continuous Cultures at Two Residence Times—Insights From qPCR Measurements and Viral Dynamics Modeling
por: Tapia, Felipe, et al.
Publicado: (2019)

Purification of modified vaccinia virus Ankara from suspension cell culture
por: Jordan, Ingo, et al.
Publicado: (2015)

Cell lines from the Egyptian fruit bat are permissive for modified vaccinia Ankara
por: Jordan, Ingo, et al.
Publicado: (2009)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
por: García-Arriaza, Juan, et al.
Publicado: (2021)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
por: Okeke, Malachy I., et al.
Publicado: (2017)

A Deleted Deletion Site in a New Vector Strain and Exceptional Genomic Stability of Plaque-Purified Modified Vaccinia Ankara (MVA)
por: Jordan, Ingo, et al.
Publicado: (2019)

Flow cytometric monitoring of influenza A virus infection in MDCK cells during vaccine production
por: Schulze-Horsel, Josef, et al.
Publicado: (2008)

Production of retroviral vectors in continuous high cell density culture
por: Hein, Marc D., et al.
Publicado: (2023)

A Genotype of Modified Vaccinia Ankara (MVA) that Facilitates Replication in Suspension Cultures in Chemically Defined Medium
por: Jordan, Ingo, et al.
Publicado: (2013)

Cell culture-based production of defective interfering particles for influenza antiviral therapy
por: Wasik, Milena A., et al.
Publicado: (2017)

Expanding the Repertoire of Modified Vaccinia Ankara-Based Vaccine Vectors via Genetic Complementation Strategies
por: Garber, David A., et al.
Publicado: (2009)

The production of recombinant platelet‐derived growth factor D using the second generation modified vaccinia Ankara viral system
por: Najy, Abdo J., et al.
Publicado: (2022)

Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge
por: Pan, Youdong, et al.
Publicado: (2021)

Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors
por: Tenesaca, Shirley, et al.
Publicado: (2021)

Environmental Risk Assessment of Clinical Trials Involving Modified Vaccinia Virus Ankara (MVA)-Based Vectors
por: Goossens, Martine, et al.
Publicado: (2013)

Process intensification of EB66® cell cultivations leads to high-yield yellow fever and Zika virus production
por: Nikolay, Alexander, et al.
Publicado: (2018)

MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation
por: Genzel, Yvonne, et al.
Publicado: (2010)

Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes
por: Lülf, Anna-Theresa, et al.
Publicado: (2016)

Modified Vaccinia Virus Ankara Exerts Potent Immune Modulatory Activities in a Murine Model
por: Nörder, Miriam, et al.
Publicado: (2010)

Modified Vaccinia virus Ankara but not vaccinia virus induces chemokine expression in cells of the monocyte/macrophage lineage
por: Lehmann, Michael H, et al.
Publicado: (2015)

A modified vaccinia Ankara vaccine vector expressing a mosaic H5 hemagglutinin reduces viral shedding in rhesus macaques
por: Florek, Kelsey R., et al.
Publicado: (2017)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
por: Orlova, Olga Vladimirovna, et al.
Publicado: (2022)

Modified vaccinia Ankara–Bavarian Nordic vaccine against mpox in children
por: Turtle, Lance, et al.
Publicado: (2023)

Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?
por: Drexler, Ingo, et al.
Publicado: (2004)

Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model
por: Julander, Justin G., et al.
Publicado: (2018)

Safety and immunogenicity of mammalian cell derived and Modified Vaccinia Ankara vectored African swine fever subunit antigens in swine
por: Lopera-Madrid, Jaime, et al.
Publicado: (2017)

High cell density perfusion process for high yield of influenza A virus production using MDCK suspension cells
por: Wu, Yixiao, et al.
Publicado: (2021)

Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells
por: Lohr, Verena, et al.
Publicado: (2012)

The avian cell line AGE1.CR.pIX characterized by metabolic flux analysis
por: Lohr, Verena, et al.
Publicado: (2014)

Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligand
por: Préville, Xavier, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6des5h08ndjrl8goaau7mcfier